A thorough psychopharm explainer (numbered Q&A) on allopregnanolone (Zulresso/brexanolone) and its oral successor zuranolone for postpartum depression. Covers the mechanism (a positive allosteric modulator of GABA — a sort of endogenous benzodiazepine, floated as a possible master anxiety switch), the standard psychiatry pattern of overclaiming a new 'true mechanism,' the PMDD/PPD progesterone-crash link, the trial evidence (Kanes, Meltzer-Brody; the biphasic dose-response), the $35K pricing (defensibly high given raw allopregnanolone costs $10-20K/g, and Sage nearly went bankrupt — evidence some drug prices reflect fundamentals not just greed), the official/skeptic/troll trichotomy on how it differs from cheap benzos, the zuranolone trial saga (ROBIN/WATERFALL/MOUNTAIN/CORAL, the hacked CORAL), and calibrated predictions. Numerate, honest, useful.

Quality 70 · Strong. Strong: a rigorous, well-sourced clinical explainer that adjudicates messy evidence honestly and lands a real general point (some high drug prices reflect fundamentals); sits with Scott's other psychopharm explainers (~70).

Claude’s paradigm shift 48 · Moderate. Moderate-notable: assembles and evaluates a specific drug literature rather than originating a frame.

Real-world impact 2 · Minor. Within-discourse/practical: useful clinical/scientific explainer on a real treatment for a widely-relevant condition; modest reach.

Zounds! It's Zulresso and Zuranolone!